EyeGate Pharma Enrolls First Patient in Phase 2b Clinical Study of EGP-437 for Cataract Surgery
August 01, 2017 07:30 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Aug. 01, 2017 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and...
EyeGate Announces Completion of $10.0 Million Public Offering
June 14, 2017 16:30 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., June 14, 2017 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and...
EyeGate Announces $10.0 Million Public Offering
June 09, 2017 07:00 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., June 09, 2017 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and...
EyeGate Receives Milestone Payment from Valeant Pharmaceuticals for EGP-437 for post-operative ocular inflammation and pain in ocular surgery patients
May 22, 2017 07:30 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., May 22, 2017 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and...
EyeGate Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Business Update
May 08, 2017 08:30 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., May 08, 2017 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company that focuses on...
EyeGate Submits Investigational Device Exemption (IDE) Filing for Second Pilot Study of Ocular Bandage Gel
May 04, 2017 07:30 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., May 04, 2017 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company that focuses on...
EyeGate Pharma Strengthens Scientific Advisory Board with Appointments of Daniel S. Durrie, M.D. and Randall J. Olson, M.D.
March 13, 2017 07:30 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., March 13, 2017 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company that focuses on...
EyeGate Pharmaceuticals Reports Full-year 2016 Financial Results and Provides Business Update
February 23, 2017 16:08 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Feb. 23, 2017 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company that focuses on...
EyeGate Pharmaceuticals Announces Executive Promotions
February 06, 2017 16:01 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Feb. 06, 2017 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and...
EyeGate Pharma Announces Positive Top-line Data from First-in-Human Pilot Trial of Ocular Bandage Gel in Corneal Epithelial Defects
January 30, 2017 08:30 ET
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Jan. 30, 2017 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and...